ClinicalTrials.gg
CompletedNCT06319170Updated Jan 26, 2026Results posted

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

A Phase 1 interventional study of Olanzapine Extended Release and Olanzapine Immediate Release in Schizophrenia, Schizoaffective Disorder, sponsored by Teva Branded Pharmaceutical Products R&D LLC. Completed at 5 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Teva Branded Pharmaceutical Products R&D LLC (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 97 studies testing olanzapine in Schizophrenia — 2 open to participants now, 3 under way, 1 of them phase 3. Olanzapine · Schizophrenia.

Enrollment
53rd of 94
106 · median 114
Started
2024
the only one that year
Phase 1
7 of 97
none open now
Registered
96th of 97
by date

Among the 97 studies testing olanzapine in Schizophrenia, this one is the 53rd largest by enrollment of the 94 interventional ones that give a count, is the only one that started in 2024, is one of 7 in phase 1, and was the 96th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 97 studies testing olanzapine in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About olanzapine

Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies testing olanzapine in Schizophrenia, or all of them as a file.
02

Study summary

The primary objective of the study is to characterize the pharmacokinetics of 3 formulations of olanzapine.

A secondary objective is to evaluate the safety and tolerability of 3 formulations of olanzapine.

Another secondary objective is to characterize the pharmacokinetics of ZYPREXA.

The planned duration of the study for each participant is 19 weeks.

Read the detailed description

All participants received immediate-release ZYPREXA and then were randomized into 1 of 3 extended-release olanzapine formulations.

03

Conditions studied

  • Schizophrenia, Schizoaffective Disorder
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight >50 kg and (BMI) within the range 18.5 to 38.0 kg/m2, inclusive, at the time of screening
  • Agree to maintain current smoking or nonsmoking status at the time is obtained and throughout the trial until completion of the end of treatment or early termination (ET) visit (ie, nonsmoking participants must agree not to start smoking and participants who smoke will be excluded if they plan to discontinue smoking during the trial
  • Agree to the inpatient periods required during the trial period
  • Have a current confirmed diagnosis of schizophrenia or schizoaffective disorder according to an evaluation by the Investigator, using the , Fifth Edition (DSM-5) (American Psychiatric Association 2013a)
  • Have no ongoing or expected significant life events (eg, pending loss of housing, marital status change, long travel abroad, surgery) that could affect trial outcomes throughout the period of trial participation
  • Women may be included only if they have a negative serum beta human chorionic gonadotropin (HCG) test result at screening; they are surgically sterile (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or
  • Men must be sterile; or if they are potentially of reproductive competence and have sexual relationship with female partners of , they must use, together with their female partners, highly effective methods for the duration of the trial and for 70 days after the last dose administration

NOTE- Additional criteria apply, please contact the investigator for more information

Exclusion criteria

Exclusion Criteria:

  • Presence or have a history of diseases of the renal, hepatic, gastrointestinal, cardiovascular, or musculoskeletal system, or presence or history of clinically significant immunological, endocrine, or metabolic diseases, neurological or psychiatric disorder(s) (other than schizophrenia)
  • History or known risk of narrow-angle glaucoma
  • Uncontrolled diabetes
  • Major trauma or surgery in the 2 months before screening
  • History of or treatment of malignancy in the last 5 years, excluding resected basal cell or squamous cell carcinoma of the skin
  • The participant is a pregnant or lactating woman or plans to become pregnant during the trial or within 70 days after the last dose administration
  • Personal or family history of arrhythmia, sudden unexplained death at a young age (before 40 years) in a first-degree relative, long syndrome, personal history of syncope, or history of uncontrolled high blood pressure

NOTE- Additional criteria apply, please contact the investigator for more information

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Olanzapine (Fast-D) 425mg

    Single-dose injection

    Drug: Olanzapine Extended Release

  • Experimental
    Olanzapine (To-be-marketed) 425mg

    Single-dose injection

    Drug: Olanzapine Extended Release

  • Experimental
    Olanzapine (Slow-C) 425mg

    Single-dose injection

    Drug: Olanzapine Extended Release

  • Experimental
    ZYPREXA 5mg

    Single-dose injection

    Drug: Olanzapine Immediate Release

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Olanzapine (Extended-release Formulation)

    Time frame: Randomization Day 1 to 84 days after randomization

  2. Area Under the Plasma Concentration-time Curve From Study Drug Administration to the Last Measurable Concentration (AUC0-t) of Olanzapine (Extended-release Formulation)

    Time frame: Randomization Day 1 to 84 days after randomization

  3. Area Under the Plasma Concentration-time Curve Extrapolated to Infinity (AUC0-inf) of Olanzapine (Extended-release Formulation)

    Time frame: Randomization Day 1 to 84 days after randomization

Secondary outcomes

  1. Number of Participants With at Least 1 Treatment-emergent Adverse Event (TEAE) Over the 28-day Period Following Administration of 1 of the SC Olanzapine Formulations

    An adverse event (AE) was defined as any untoward medical occurrence in a participant who received the study drug without regard to possibility of causal relationship. A TEAE was defined as an AE that occurred after the first dose of study drug administration through the end of trial. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in the Reported AE section.

    Time frame: Randomization Day 1 through Randomization Day 29

  2. Number of Participants With at Least 1 Serious Adverse Event (SAE) Over the 28-day Period Following Administration of 1 of the SC Olanzapine Formulations

    The SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in the Reported AE section.

    Time frame: Randomization Day 1 through Randomization Day 29

  3. Cmax of ZYPREXA (Immediate-release Formulation)

    Time frame: Up to 24 hours after administration of ZYPREXA (Day 4)

  4. AUC0-t of ZYPREXA (Immediate-release Formulation)

    Time frame: Predose (Day 4) up to 216 hours after administration of ZYPREXA (Day 13)

  5. Apparent Plasma Terminal Elimination Rate Constant (λz) of ZYPREXA (Immediate-release Formulation)

    Time frame: Predose (Day 4) up to 216 hours after administration of ZYPREXA (Day 13)

07

Results

Posted Jan 26, 2026

Participant flow

1-Day Treatment Period
Participant flow — 1-Day Treatment Period
MilestoneZYPREXACohort 1: Olanzapine (Fast-D)Cohort 2: Olanzapine (To-be-marketed)Cohort 3: Olanzapine (Slow-C)
Started106000
Received at least 1 dose of study drug98000
Completed91000
Not completed15000
Withdrew: Enrolled but not treated8000
Withdrew: Withdrawal by subject3000
Withdrew: Lost to follow-up2000
Withdrew: Other than specified2000
28-Day Treatment Period
Participant flow — 28-Day Treatment Period
MilestoneZYPREXACohort 1: Olanzapine (Fast-D)Cohort 2: Olanzapine (To-be-marketed)Cohort 3: Olanzapine (Slow-C)
Started0293131
Received at least 1 dose of study drug0293131
Completed0282931
Not completed0120
Withdrew: Withdrawal by subject0020
Withdrew: Other than specified0100
8-Week Follow-up Period
Participant flow — 8-Week Follow-up Period
MilestoneZYPREXACohort 1: Olanzapine (Fast-D)Cohort 2: Olanzapine (To-be-marketed)Cohort 3: Olanzapine (Slow-C)
Started0282931
Completed0272730
Not completed0121
Withdrew: Lost to follow-up0110
Withdrew: Withdrawal by subject0010
Withdrew: Other than specified0001

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) of Olanzapine (Extended-release Formulation)
Time frame:
Randomization Day 1 to 84 days after randomization
Reported as:
Geometric mean · nanograms (ng)/milliliter (mL)
Maximum Observed Plasma Concentration (Cmax) of Olanzapine (Extended-release Formulation)
nanograms (ng)/milliliter (mL)Cohort 1: Olanzapine (Fast-D)Cohort 2: Olanzapine (To-be-marketed)Cohort 3: Olanzapine (Slow-C)
Maximum Observed Plasma Concentration (Cmax) of Olanzapine (Extended-release Formulation)39.26 ± 45.1035.62 ± 67.5529.68 ± 50.13
PrimaryArea Under the Plasma Concentration-time Curve From Study Drug Administration to the Last Measurable Concentration (AUC0-t) of Olanzapine (Extended-release Formulation)
Time frame:
Randomization Day 1 to 84 days after randomization
Reported as:
Geometric mean · hours*ng/mL
Area Under the Plasma Concentration-time Curve From Study Drug Administration to the Last Measurable Concentration (AUC0-t) of Olanzapine (Extended-release Formulation)
hours*ng/mLCohort 1: Olanzapine (Fast-D)Cohort 2: Olanzapine (To-be-marketed)Cohort 3: Olanzapine (Slow-C)
Area Under the Plasma Concentration-time Curve From Study Drug Administration to the Last Measurable Concentration (AUC0-t) of Olanzapine (Extended-release Formulation)20994.08 ± 33.7720185.90 ± 47.3518461.94 ± 35.44
PrimaryArea Under the Plasma Concentration-time Curve Extrapolated to Infinity (AUC0-inf) of Olanzapine (Extended-release Formulation)
Time frame:
Randomization Day 1 to 84 days after randomization
Reported as:
Geometric mean · hours*ng/mL
Area Under the Plasma Concentration-time Curve Extrapolated to Infinity (AUC0-inf) of Olanzapine (Extended-release Formulation)
hours*ng/mLCohort 1: Olanzapine (Fast-D)Cohort 2: Olanzapine (To-be-marketed)Cohort 3: Olanzapine (Slow-C)
Area Under the Plasma Concentration-time Curve Extrapolated to Infinity (AUC0-inf) of Olanzapine (Extended-release Formulation)21703.07 ± 35.0622146.09 ± 42.7719011.66 ± 37.21
SecondaryNumber of Participants With at Least 1 Treatment-emergent Adverse Event (TEAE) Over the 28-day Period Following Administration of 1 of the SC Olanzapine Formulations

An adverse event (AE) was defined as any untoward medical occurrence in a participant who received the study drug without regard to possibility of causal relationship. A TEAE was defined as an AE that occurred after the first dose of study drug administration through the end of trial. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in the Reported AE section.

Time frame:
Randomization Day 1 through Randomization Day 29
Reported as:
Count of participants · Participants
Number of Participants With at Least 1 Treatment-emergent Adverse Event (TEAE) Over the 28-day Period Following Administration of 1 of the SC Olanzapine Formulations
ParticipantsCohort 1: Olanzapine (Fast-D)Cohort 2: Olanzapine (To-be-marketed)Cohort 3: Olanzapine (Slow-C)
Number of Participants With at Least 1 Treatment-emergent Adverse Event (TEAE) Over the 28-day Period Following Administration of 1 of the SC Olanzapine Formulations9129
SecondaryNumber of Participants With at Least 1 Serious Adverse Event (SAE) Over the 28-day Period Following Administration of 1 of the SC Olanzapine Formulations

The SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in the Reported AE section.

Time frame:
Randomization Day 1 through Randomization Day 29
Reported as:
Count of participants · Participants
Number of Participants With at Least 1 Serious Adverse Event (SAE) Over the 28-day Period Following Administration of 1 of the SC Olanzapine Formulations
ParticipantsCohort 1: Olanzapine (Fast-D)Cohort 2: Olanzapine (To-be-marketed)Cohort 3: Olanzapine (Slow-C)
Number of Participants With at Least 1 Serious Adverse Event (SAE) Over the 28-day Period Following Administration of 1 of the SC Olanzapine Formulations010
SecondaryCmax of ZYPREXA (Immediate-release Formulation)
Time frame:
Up to 24 hours after administration of ZYPREXA (Day 4)
Reported as:
Geometric mean · ng/mL
Cmax of ZYPREXA (Immediate-release Formulation)
ng/mLZYPREXA
Cmax of ZYPREXA (Immediate-release Formulation)11.09 ± 82.89
SecondaryAUC0-t of ZYPREXA (Immediate-release Formulation)
Time frame:
Predose (Day 4) up to 216 hours after administration of ZYPREXA (Day 13)
Reported as:
Geometric mean · hours*ng/mL
AUC0-t of ZYPREXA (Immediate-release Formulation)
hours*ng/mLZYPREXA
AUC0-t of ZYPREXA (Immediate-release Formulation)264.22 ± 48.14
SecondaryApparent Plasma Terminal Elimination Rate Constant (λz) of ZYPREXA (Immediate-release Formulation)
Time frame:
Predose (Day 4) up to 216 hours after administration of ZYPREXA (Day 13)
Reported as:
Mean · 1/hour
Apparent Plasma Terminal Elimination Rate Constant (λz) of ZYPREXA (Immediate-release Formulation)
1/hourZYPREXA
Apparent Plasma Terminal Elimination Rate Constant (λz) of ZYPREXA (Immediate-release Formulation)0.0159 ± 0.00381

Adverse events

Collected over Day 1 up to Day 84. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ZYPREXA0/106 (0%)0/98 (0%)18/98 (18.4%)
Cohort 1: Olanzapine (Fast-D)0/29 (0%)0/29 (0%)8/29 (27.6%)
Cohort 2: Olanzapine (To-be-marketed)0/31 (0%)1/31 (3.2%)11/31 (35.5%)
Cohort 3: Olanzapine (Slow-C)0/31 (0%)0/31 (0%)6/31 (19.4%)
Most frequent serious events
Most frequent serious events
EventZYPREXACohort 1: Olanzapine (Fast-D)Cohort 2: Olanzapine (To-be-marketed)Cohort 3: Olanzapine (Slow-C)
Suicidal ideationPsychiatric disorders0/980/291/310/31
Most frequent other events
Most frequent other events
EventZYPREXACohort 1: Olanzapine (Fast-D)Cohort 2: Olanzapine (To-be-marketed)Cohort 3: Olanzapine (Slow-C)
Injection site painGeneral disorders0/982/293/310/31
SomnolenceNervous system disorders5/981/293/312/31
Injection site irritationGeneral disorders0/982/290/311/31
Psychotic disorderPsychiatric disorders0/982/291/311/31
Urinary tract infectionInfections and infestations5/980/292/310/31
Alanine aminotransferase increasedInvestigations1/980/291/312/31
Aspartate aminotransferase increasedInvestigations1/980/291/312/31
Blood creatine phosphokinase increasedInvestigations1/981/292/310/31
HeadacheNervous system disorders6/980/291/310/31

Baseline characteristics

The Enrolled Analysis Set included all participants who signed an informed consent form (ICF) and were enrolled in the trial.

Age, Continuous
Age, Continuous(years)ZYPREXA Only (Not Randomized)Cohort 1: Olanzapine (Fast-D)Cohort 2: Olanzapine (To-be-marketed)Cohort 3: Olanzapine (Slow-C)Total
Mean37.9 ± 11.9545.7 ± 11.8843.3 ± 11.3942.1 ± 11.4842.8 ± 11.72
Sex: Female, Male
Sex: Female, Male(Participants)ZYPREXA Only (Not Randomized)Cohort 1: Olanzapine (Fast-D)Cohort 2: Olanzapine (To-be-marketed)Cohort 3: Olanzapine (Slow-C)Total
Female21161029
Male1318252177
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ZYPREXA Only (Not Randomized)Cohort 1: Olanzapine (Fast-D)Cohort 2: Olanzapine (To-be-marketed)Cohort 3: Olanzapine (Slow-C)Total
Hispanic or Latino3711829
Not Hispanic or Latino1222202377
Unknown or Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ZYPREXA Only (Not Randomized)Cohort 1: Olanzapine (Fast-D)Cohort 2: Olanzapine (To-be-marketed)Cohort 3: Olanzapine (Slow-C)Total
Race — White67141037
Race — Black or African American922141964
Race — Asian00022
Race — Native Hawaiian or Other Pacific Islander00101
Race — Other00202
08

Study locations

5 sites
  • Teva Investigational Site 15730
    Los Alamitos, California 90720, United States
  • Teva Investigational Site 15727
    Hollywood, Florida 33024, United States
  • Teva Investigational Site 15729
    Atlanta, Georgia 30331, United States
  • Teva Investigational Site 15728
    Decatur, Georgia 30030, United States
  • Teva Investigational Site 15726
    Marlton, New Jersey 08053, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be assessed for scientific merit, product approval status, and conflicts of interest. If the request is approved, patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please visit USMedInfo@tevapharm.com to make your request.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Jan 2025, 9 months.

Results were first posted in Jan 2026, 1 year after primary completion.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 9 months is close to that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2024
First posted
Mar 19, 2024
StartActual
Mar 28, 2024
Primary completionActual
Jan 15, 2025
CompletionActual
Jan 20, 2025
Results first posted
Jan 26, 2026
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06319170
Responsible party
Sponsor
First posted
Mar 19, 2024
Start date
Mar 28, 2024
Primary completion
Jan 15, 2025
Completion
Jan 20, 2025
Results posted
Jan 26, 2026
Last update
Jan 26, 2026

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olanzapine

Start the discussion